Last reviewed · How we verify
Vaso-occlusive crisis in sickle cell disease
Approved treatments
- Selg1 · Novartis
Selg1 works by binding to P-selectin, preventing it from interacting with its ligands. - ADAKVEO · NOVARTIS PHARMS CORP
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Vaso-occlusive crisis in sickle cell disease patent landscape — cliff calendar, originator estates, attackable patents
- Vaso-occlusive crisis in sickle cell disease treatment landscape brief
- Vaso-occlusive crisis in sickle cell disease treatment updates RSS
Frequently asked questions about Vaso-occlusive crisis in sickle cell disease
What drugs treat Vaso-occlusive crisis in sickle cell disease?
Tracked treatments include Selg1, ADAKVEO.
What is the treatment for Vaso-occlusive crisis in sickle cell disease?
Standard treatment for Vaso-occlusive crisis in sickle cell disease includes Selg1, ADAKVEO. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Vaso-occlusive crisis in sickle cell disease patent cliff · Vaso-occlusive crisis in sickle cell disease CI report
- Treatment: Selg1 · Novartis
- Treatment: ADAKVEO · NOVARTIS PHARMS CORP
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing